GLP-1
GLP-1 Drugs Are Entering the Alcohol Conversation
A Lancet RCT suggests semaglutide may affect heavy drinking days in adults with alcohol use disorder and obesity—but the story is biology, not hype.
GLP-1
A Lancet RCT suggests semaglutide may affect heavy drinking days in adults with alcohol use disorder and obesity—but the story is biology, not hype.
GLP-1
The FDA's April 30, 2026 proposed rule permanently closes the door on bulk compounded GLP-1s. Here's what that means for your peptide therapy protocol — and your real options.